Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Centre Hospitalier St Anne
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07210112CT.gov Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ) | — | Not Yet Recruiting | — | — | — |
NCT03852160CT.gov A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression | — | Withdrawn | — | — | — |
NCT01896349CT.gov Interpersonal Psychotherapy for Treatment Resistant Depression | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trazodone (this asset) | Centre Hospitalier St Anne | P3 | B · 63 |
| Brexpiprazole | Dr. Albert Kar-Kin Chung | P4 | A |
| Jnj-54135419 | Chinese PLA General Hospital | P4 | BBB |
| Saredutant | Sanofi | P3 | BBB |
| VENLOR | Janssen Research & Development, LLC | P4 | BBB |
| Citalopram | Western University, Canada | P4 | BBB |
| Escitalopram | Poznan University of Medical Sciences | P4 | BBB |
| Paroxetine | Brigham and Women's Hospital | P4 | BBB |
| Lithium, Elemental | Rakitzi, Stavroula | P4 | BBB |
+42 more in the Depressive Disorder cohort
Other indications for Trazodone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Sleep Disorder | — | P4 | BB · 71 |
| Sleep Apnea Syndrome | — | P4 | BB · 66 |
| Parasomnia, Sleep Bruxism Type | — | P4 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Trazodone in Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trazodone-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →